Sulindac inhibits the NF-κB pathway. Sulindac is a non-steroidal anti-inflammatory drug. Sulindac reduces the level and activity of several cyclin-dependent kinases (CDKs) and induces apoptosis. Sulindac metabolizes to sulindac sulfide (sc-200118), a Cox (cyclooxygenase) inhibitor that represses ras signaling, and sulindac sulfone (sc-200120), an antitumor agent. Sulindac is an inhibitor of Cox-1 and Cox-2.
1. Shen, T.Y. and Winter, C.A. 1977. Adv. Drug Res. 12: 290- 245. PMID: 343530 2. Taylor, M.T., et al. 2000. Cancer Res. 60: 6607-6610. PMID: 11118042 3. Haanen, C. 2001. Curr. Opin. Invest. Drugs. 2: 677-683. PMID: 11569947
Soluble in water (0.05 mg/ml at 25° C), methanol (50 mg/ml), ethanol (9 mg/ml at 25° C), DMSO (71 mg/ml at 25° C), and DMF (~ 30 mg/ml).
Store at room temperature
581.64° C at 760 mmHg (Predicted)
~1.39 g/cm3 (Predicted)
n20D 1.67 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
Haanen (PubMed ID 11569947) found that SulindacHaanen (PubMed ID 11569947) found that Sulindac showed anticancer properties by inhibiting cyclic-GMP phosphodiesterase, increasing cGMP to activate protein kinase G and inducing transcription of caspase genes, resulting in apoptosis. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn